Market revenue in 2021 | USD 459.0 million |
Market revenue in 2030 | USD 894.2 million |
Growth rate | 7.7% (CAGR from 2021 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Beovu |
Historical data | 2017 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu |
Key market players worldwide | Roche Holding AG ADR, Novartis AG ADR, Bayer AG, Pfizer Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, Biogen Inc, Samsung Bioepis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to age related macular degeneration market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 53.73% in 2021. Horizon Databook has segmented the UK age related macular degeneration market based on eylea, lucentis, beovu covering the revenue growth of each sub-segment from 2017 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UK age related macular degeneration market , including forecasts for subscribers. This country databook contains high-level insights into UK age related macular degeneration market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account